A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma
Latest Information Update: 08 Nov 2021
At a glance
- Drugs Universal LCAR-BCX cell therapy-Nanjing Legend Biotech (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 01 Nov 2021 Status changed from recruiting to active, no longer recruiting.
- 02 Nov 2020 New trial record